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Background: Few data on cancer mortality have been published for Mexico over the last few
decades. It is therefore of interest to conduct a systematic and updated analysis of cancer mortality
in this country.
Patients and methods: Age-standardised (world population) mortality rates, at all ages and trun-
cated at age 35–64 years, from major cancers and all cancers combined were computed on the basis
of certified deaths derived from the World Health Organization database for the period 1970–99.
Results: Mortality rates for all neoplasms showed an upward trend in men of all ages (from
58.2/100 000 in 1970–74 to 87.1/100 000 in 1995–99) and in middle-aged men (from 76.1 to
93.7/100 000, respectively). This reflects the rise until the early 1990s in lung cancer mortality (from
8.1/100 000 in 1970–74 to 15.6/100 000 in 1995–99) and prostate cancer (from 5.5 to 12.2/100 000,
respectively). In women, overall mortality rates showed an increase between the early 1970s
(75.4/100 000) and the late 1990s (82.3/100 000). Total cancer mortality rates remained low, how-
ever, compared with other American countries (e.g. 153.3/100 000 men and 108.6/100 000 women
in 1999 in the United States). Truncated rates were stable (126.5/100 000 in 1970–74 and
125.8/100 000 in 1995–99), although they were much higher than overall rates, reflecting exceed-
ingly high rates for uterine (mostly cervical) cancer mortality in middle-aged women (29.5/100 000
in 1995–99).
Conclusions: Total cancer mortality in Mexico has remained comparably low on a worldwide scale,
and the upward trends in mortality rates for lung and other tobacco-related neoplasms have tended
to level off over the last decade. However, steady rises have been observed for other major cancers,
including prostate and breast. Cervical cancer remains a major health problem in women.
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Introduction
Data and statistics on cancer mortality over the last few
decades are available for most developed countries in Europe,
North America, Australia and Japan [1], but fewer data have
been published for Latin America, including Mexico.
Mexico has a territorial extension of  2 million km2 and
 97 million inhabitants [2]. Information on major causes of
death has been available since 1922 [3] and mortality data
have been provided to the World Health Organization (WHO)
since 1955. Death certificates are routinely signed by a doctor,
checked at state level, and finally registered and collected in a
repository at the National Institute of Statistics, Geography
and Informatics.
Mexican data on cancer mortality up to 1986 have been
considered in a summary report of cancer mortality in the
Americas [4]. Among the interesting aspects of this report,
low mortality rates were registered for several major cancer
sites, including mouth and pharynx, oesophagus, colorectum,
lung, breast and prostate, and high rates were registered for
cancer of the (cervix) uteri [5]. Gastric cancer rates were
appreciably higher than in North America, although they were
relatively low compared with other Latin American countries.
Steady upward trends were observed for cancer of the lung
and for several other tobacco-related neoplasms, mainly in
men [6], and also for cancers of the female breast. In contrast,
stomach cancer mortality showed an appreciable downward
trend, and colorectal cancer rates remained low over time [4].
Other analyses on mortality from selected cancers in
Mexico for the period 1980–1995 reported increasing trends
for cancers of the lung [7], breast [8], colorectum [9], prostate
[10] and stomach [11]. Inconsistent trends were reported for
cervical cancer [12–14].
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It is therefore of interest to conduct a systematic and
updated analysis of cancer mortality in this country. The avail-
ability of such data is of importance and interest for descrip-
tive epidemiology, as well as for the definition of priorities in
public health policies.
Patients and methods
Certified deaths for the six quinquennia considered (from 1970–74 to
1995–99), stratified for sex and 5-year age groups, from 13 selected can-
cer sites and for total cancer, were derived from the WHO database [15].
Data for 1984 were unavailable for all neoplasms. Mortality data for ovar-
ian and testicular cancers were unavailable for 1970 and 1975–97, and
bladder cancer data were unavailable for 1970 and 1975–78. No extrapol-
ations were made for missing data.
During the calendar periods considered, three different revisions of the
International Classification of Diseases (ICD) were used [16–18]. Classifi-
cation of cancer deaths was thus recoded for all calendar periods accord-
ing to the IX Revision of the ICD [17, 19]. To reduce classification
problems and improve comparability of data, we pooled all intestinal can-
cers (chiefly colon and rectum), all uterine cancers (cervix and corpus)
and all leukaemias. No reliable data were available for several rarer can-
cers (i.e. gallbladder, soft tissue sarcomas, lymphomas and thyroid) and a
few other sites (i.e. pancreas, kidney and brain), which involve major dif-
ficulties in diagnosis and certification [20]. Data for liver, bone and skin
cancer were excluded from the present analysis due to potential problems
with reliability of certification.
Estimates of the resident population, based on official censuses, were
obtained from the same WHO database for the period 1970–95 (excluding
1984) [15] and from the Pan American Health Organization (PAHO) [21]
for 1996–99. Since the PAHO database provided only data for the total
population, the 5-year age groups were estimated by interpolating from
the 1995 WHO distribution. From the matrices of certified deaths and resi-
dent population, age-specific rates for each 5-year age group and calendar
period were computed. Age-standardised rates, at all ages and truncated at
age 35–64 years, were computed by the direct method on the basis of
the world standard population [22]. Since this is essentially a descriptive
report, no inference was made on the statistical significance of rates and
trends.
Results
For each cancer site, two tables are given, which display
world-standardised mortality rates for both men and women of
all ages (Table 1) and truncated at age 35–64 years (Table 2)
for the quinquennia 1970–74 and 1995–99, and the corre-
sponding percentage changes.
Figure 1 shows the trends in world-standardised mortality
rates for each cancer site (for men and women, at all ages and
truncated) for the calendar period 1970–99. Overall mortality
from cancers of the mouth and pharynx in men increased from
1.36/100 000 in 1970–74 to 1.85/100 000 in 1985–89, and
levelled off thereafter to reach a value of 1.79 in 1995–99. A
similar trend was found in middle-aged men (35–64 years),
whose rates varied from 1.95/100 000 in 1970–74 to
2.35/100 000 in 1995–99. Mortality from cancer of the mouth
and pharynx was much lower in women of all ages, and
showed a slight upward trend until the mid-1980s
(0.59/100 000 in 1970–74 and 0.74/100 000 in 1985–89),
which then levelled off during the 1990s (0.69/100 000 in
1995–99). Similarly, in middle-aged women, rates increased
from 0.80/100 000 in 1970–74 to 0.89/100 000 in 1995–99.
A similar pattern in mortality trends was observed for oeso-
phageal cancer, the overall mortality of which in men
increased until the late 1980s (from 1.52/100 000 in 1970–74
to 1.94/100 000 in 1985–89), and then stabilised at a value of
1.81/100 000 in 1995–99. In men aged 35–64 years, rates
showed no clear trend, varying from 2.08/100 000 in 1970–74
to 2.05/100 000 in 1995–99. Oesophageal cancer mortality in
women was lower, and showed a slight decrease over time.
Table 1. Age-standardised (world population) death rates (per 100 000) from selected cancers or groups of cancers in Mexico, 1970–99
Cancer site ICD IX Men Women
1970–74 1995–99 Percent change
95–99/70–74
1970–74 1995–99 Percent change
95–99/70–74
Mounth or pharynx 140–149 1.36 1.79 31.96 0.59 0.69 16.58
Oesophagus 150 1.52 1.81 18.85 0.75 0.66 11.50
Stomach 151 9.90 9.17 7.42 8.70 6.58 24.36
Intestines, chiefly colon and rectum 152–154, 159.0 2.64 3.83 45.28 3.24 3.42 5.40
Larynx 161 2.05 2.44 18.95 0.58 0.42 27.38
Lung 162 8.14 15.55 91.00 4.05 5.99 47.90
Breast 174 – – – 5.22 9.65 84.90
Uterus, cervix and corpus 179–182 – – – 19.09 15.35 19.59
Ovary and other uterine adnexa 183 – – – 1.81 3.41 88.74
Prostate 185 5.47 12.24 124.03 – – –
Testis 186 0.38 0.68 79.51 – – –
Bladder 188 0.85 1.42 67.20 0.39 0.57 45.17
Leukaemias 204–208 2.41 4.03 67.45 2.13 3.28 54.13
All neoplasms, benign and malignant 140–239 58.18 87.14 49.77 75.43 82.28 9.09
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Between 1970–74 and 1995–99 it changed from 0.75 to
0.66/100 000 in women of all ages, and from 1.01 to
0.77/100 000 in middle-aged women.
Stomach cancer mortality rates in men showed a steady
downward trend from the beginning of the 1970s to the
late 1990s, changing from 9.90/100 000 in 1970–74 to
9.17/100 000 in 1995–99. Corresponding values for the trun-
cated age group were 13.01 and 10.82/100 000. Stomach can-
cer rates in women declined from 8.70/100 000 in 1970–74 to
6.58/100 000 in 1995–99 for women of all ages, and from
11.04 to 8.22/100 000 in middle-aged ones.
Rates for intestinal cancer showed inconsistent patterns
over time for both sexes, with a downward trend until the
beginning of the 1980s and an upward one thereafter. Rates,
however, were very low, i.e. <5/100 000 for both sexes and all
age groups.
Laryngeal cancer rates for men rose from 2.05/100 000 in
1970–74 to 2.58/100 000 in 1990–94, and then levelled off to
2.44/100 000 in 1995–99. In middle-aged men, rates remained
stable at around 3/100 000. In women, rates were much
lower than in men, and showed a downward trend over time,
with both overall and truncated rates reaching a value of
 0.50/100 000 in 1995–99.
Overall mortality from lung cancer in men showed a strong
rising trend until the end of the 1980s (from 8.14/100 000 in
1970–74 to 15.92/100 000 in 1985–89), and then stabilised
(15.55/100 000 in 1995–99). In middle-aged men, after an
increase until the late 1980s, lung cancer rates declined to
16.65/100 000 in 1995–99. Rates for lung cancer mortality in
women were much lower than in men, but showed a steady
upward trend. In women of all ages, they varied from
4.05/100 000 in 1970–74 to 5.84/100 000 in 1985–89 and
5.99/100 000 for 1995–99; in middle-aged women, these
rates rose from 5.99/100 000 in 1970–74, to 7.69/100 000 in
1985–89 and 7.27/100 000 in 1995–99.
Female breast cancer mortality showed a marked upward
trend, particularly among women aged 34–64 years, who also
showed much higher absolute values. It rose to 9.65/100 000
in women of all ages and to 20.71/100 000 in middle-aged
women.
Mortality rates from uterine cancers showed a decreasing
trend. They dropped from 19.09/100 000 in 1970–74 to
15.35/100 000 in 1995–99 for women of all ages, and from
39.16/100 000 to 29.52/100 000 in middle-aged ones, when
most deaths are due to cervical cancer.
Data for ovarian cancer were available only for the years
1971–74 and 1997–99. Between these two periods, mortality
increased from 1.81 to 3.41/100 000 in women of all ages, and
from 3.69 to 6.40/100 000 in middle-aged women.
Total mortality from prostate cancer rose steadily during
the period studied, with rates increasing from 5.47/100 000 in
1970–74 to 12.24/100 000 in 1995–99. In the truncated age
group, rates were much lower and showed a less marked
increasing trend, with variation from 3.19/100 000 in 1970–74
to 5.38/100 000 in 1995–99.
Overall testicular cancer mortality rates were 0.38/100 000
in 1971–74 and 0.68/100 000 in 1997–99; corresponding
rates for middle-aged men were 0.48 and 0.72/100 000.
Bladder cancer mortality rates in men rose during the 1970s
and levelled off thereafter to a value of 1.42/100 000 in 1995–
99 for men of all ages, and to 1.21/100 000 for middle-aged
men. In women, rates were lower and increasing trends were
smaller, but steady throughout the whole period studied.
Table 2. Age-standardised (world population) truncated (35–64 years) death rates (per 100 000) from selected cancers or groups of cancers in Mexico,
1970–99
Cancer site ICD IX Men Women
1970–74 1995–99 Percent change
95–99/70–74
1970–74 1995–99 Percent change
95–99/70–74
Mounth or pharynx 140–149 1.95 2.35 20.26 0.80 0.89 10.98
Oesophagus 150 2.08 2.05 1.16 1.01 0.77 23.12
Stomach 151 13.01 10.82 16.82 11.04 8.22 25.54
Intestines, chiefly colon and rectum 152–154, 159.0 3.43 4.94 43.91 4.20 4.44 5.78
Larynx 161 2.94 2.92 0.58 0.86 0.50 42.49
Lung 162 12.02 16.65 38.55 5.99 7.27 21.31
Breast 174 – – – 11.17 20.71 85.44
Uterus, cervix and corpus 179–182 – – – 39.16 29.52 24.61
Ovary and other uterine adnexa 183 – – – 3.69 6.40 73.45
Prostate 185 3.19 5.38 68.76 – – –
Testis 186 0.48 0.72 51.01 – – –
Bladder 188 0.85 1.21 42.14 0.47 0.53 10.83
Leukaemias 204–208 2.57 3.97 54.21 2.52 3.67 45.71
All neoplasms, benign and malignant 140–239 76.05 93.72 23.23 126.47 125.76 0.57
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Figure 1. Trends in age-standardised (world population) death rates from major cancer sites and total cancer mortality in Mexico, 1970–99. Men, all
ages solid lines/crosses; men, 35–64 years broken lines/crosses; women solid lines/squares, all ages; women, 35–64 years broken lines/squares.
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Rates for leukaemias showed a rising trend for both sexes.
For men, overall rates rose from 2.41/100 000 in 1970–74 to
4.03/100 000 in 1995–99, while truncated rates rose from 2.57
to 3.97/100 000, respectively. They rose from 2.13/100 000 in
1970–74 to 3.28/100 000 in 1995–99 for women of all ages,
and from 2.52 to 3.67/100 000 for middle-aged women.
Mortality rates for all neoplasms (benign and malignant)
showed a rising trend for men of all ages (from 58.18/100 000
in 1970–74 to 87.14/100 000 in 1995–99), and for middle-
aged men (from 76.05 to 93.72/100 000, respectively). In
women, overall mortality rates showed a slight increase
from the early 1970s (75.43/100 000) to the late 1990s
(82.28/100 000); truncated rates were stable (126.47/100 000
in 1970–74 and 125.76/100 000 in 1995–99), although they
were much higher than overall mortality, reflecting exceed-
ingly high rates for uterine (mainly cervical) cancer mortality
in middle-aged women.
Discussion
When interpreting trends in cancer mortality, it is important to
consider the problems of death certification reliability and
validity [23, 24]. In general, for several common cancer sites
including lung, stomach and breast, death certification is suffi-
ciently reliable to permit meaningful inference with respect to
trends [4]. Greater caution is required for the few cancer sites
whose diagnosis and certification may be largely influenced
by the greater availability and utilisation of diagnostic
techniques, and by the increased accuracy of death certification,
including, among others, those of the colorectum, liver, bone,
soft tissue sarcomas, prostate, myelomas and other lymphoid
neoplasms. Some of these cancers, involving major difficulties
in diagnosis and certification, were excluded from the present
analyses (i.e. liver, bone, skin, sarcomas and myelomas).
The present updated analysis indicates that cancer mortality
in Mexico has remained comparably low on a worldwide
scale [1], although a moderate upward trend in total cancer
mortality has been observed during the last three decades, par-
ticularly in men. This reflects the patterns for various major
cancer sites, such as the earlier rises in lung and other
tobacco-related neoplasms, as well as those for breast and
prostate cancer.
Mortality rates for cancers of the mouth and pharynx, oeso-
phagus and larynx were low in Mexico for both sexes, as com-
pared with most American and European countries [1]. The
pattern in trends in men was, however, consistent with that
observed in several European countries [25], with increasing
rates until the mid-1980s and a tendency to decrease there-
after. No major trends over time were shown in women,
whose rates were remarkably low. Since all these neoplasms
are strongly related to tobacco and alcohol consumption [26],
recent trends in mortality suggest a change in the exposure to
these two major risk factors over the last decade, particularly
in Mexican men, although consumption data are only avail-
able for tobacco [27]. The average annual number of ciga-
rettes per adult, based on sale data, decreased from 1600 in
1970–72 to 970 in 1990–92, although there are uncertainties
surrounding these figures. According to a national interview-
based survey, the prevalence of current smokers among urban
residents decreased from 43.6% to 38.3% in men, and from
16.0% to 14.4% in women between 1971 and 1990 [27].
Additional factors, mainly related to diet, may also have had
some effect on recent trends of upper digestive and respiratory
tract neoplasms [28], although no analytical data exist on the
association between diet and these cancers in the Mexican
population.
As in most developed and developing countries, stomach
cancer rates have been steadily and appreciably declining in
Mexico for both sexes over the last few decades. In the late
1990s, Mexican gastric cancer rates were still more than two-
fold higher than those of the United States [1], but comparable
to those observed in several European countries [25]. The fall
in gastric cancer is generally attributed to a more varied and
affluent diet [29], together with improvements in food storage
and conservation, including refrigeration [30], and a decline in
Helicobacter pylori infection [31].
All intestinal cancers were combined in our analyses, since
the distinction between colon and rectum may pose some
problems (several cancers arise in the recto-sigmoid junction
[20, 32]), and a large proportion of colorectal cancer deaths
are classified as ‘intestines, site of origin unspecified’ (ICD IX
159,0). Mortality from cancer of the colorectum showed
discontinuous trends over the three decades considered, with a
sudden fall between 1970 and 1985 and a subsequent
rise, which could be related to changes in diagnosis and
certification criteria, such as the classification of other and
non-specified digestive tract neoplasms. These difficulties not-
withstanding, and despite a recent rise in mortality, intestinal
cancer rates remain exceedingly low in Mexico compared
with other countries in North America and Europe, as well as
in Latin America [4]. This could essentially be related to the
Mexican diet, including its high fibre and vegetable content,
which has been changing over recent decades [33]. A deeper
understanding of the real Mexican colorectal mortality rates
and their potential determinants would be of major relevance
for colorectal cancer control in other countries, too.
The rise in male lung cancer mortality between the 1970s
and the early 1990s, and the subsequent levelling off in all
men, and decline in middle-aged men, are of specific interest
since they indicate that young and middle-aged Mexican men
have been less frequently smokers over recent decades [27].
In particular, the recent trends in the truncated age group indi-
cate that overall lung cancer rates are unlikely to rise substan-
tially in the near future. On an absolute level, lung cancer
rates in Mexican men are appreciably lower than those regis-
tered in North America or most European countries [1]. For
women, the moderate upward trends in lung mortality rates
over the last decade, together with the persisting low absolute
values of lung cancer mortality (i.e. less than one-quarter of
those in the United States), indicate that a major epidemic of
lung cancer is unlikely to occur in the near future. These
favourable trends notwithstanding, lung cancer is one of
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the leading causes of death in Mexico [34], and prevention of
tobacco use remains a major public health priority in this
population.
Although breast cancer rates in Mexico remain at relatively
low levels compared with North America or Europe [1], they
have been rising steadily over the last three decades. The
increase is likely to be related to changes in the reproductive
habits of subsequent cohorts of Mexican women, and in par-
ticular to decreased fertility in several Mexican states in recent
decades [8]. The use of exogenous hormones, as well as the
increased prevalence of obesity [35] and dietary factors [36],
may also have played a role in the recent upward trend in
breast cancer mortality. In the absence of the effective adop-
tion of screening, and of therapeutic advantage treatments
breast cancer mortality in Mexico is likely to increase further
in the near future [37].
On the basis of death certification it was not possible to dis-
tinguish cancers arising from the cervix and the corpus uteri
(endometrium), since a substantial proportion of deaths from
uterine cancer are attributed to ‘uterus unspecified’. However,
since endometrial cancer mortality is rare in young women,
trends in young and middle-aged women are largely due to
cervical cancer. Uterine cancer rates were exceedingly high in
Mexico, accounting for almost one in six of all cancer deaths
in women. This is essentially due to high rates of cervical can-
cer, as also indicated by the high mortality in young and
middle-aged women. Although a decline of >30% in uterine
cancer mortality in middle-aged women has been observed
over the last three decades, the truncated rate of 29.3/100 000
in 1999 was still more than three-fold higher than in the Euro-
pean Union [25] and North America, and also higher than in
most other Latin American countries [5]. This essentially
reflects the inadequate utilisation of cervical screening
[38–40], the implementation of which therefore remains a pri-
ority with respect to cancer control among Mexican women.
Ovarian cancer rates were approximately two-fold higher in
1999 compared with 1971, although they remained compar-
ably low on an international scale [1]. As for breast cancer,
the upward trends in ovarian cancer rates can be related to the
declined parity of subsequent generations of Mexican women,
although modifications to dietary and other lifestyle factors
may also have played some role in changing ovarian cancer
mortality rates [41].
Overall, prostate cancer rates have increased by >140%
during the last three decades, approaching levels comparable
to those of North America and several European countries
[1, 22]. The rising trend was smaller in the truncated rates,
suggesting that recent changes and improvements in diagnosis
and certification are likely to have played a major role in the
trends registered [42].
Rates for cancer of the testis were higher in 1998–99 than
in 1971. This probably reflects a real increase in the incidence,
together with inadequate adoption of modern platinum-based
chemotherapy regimens, which have substantially reduced
mortality from testicular cancer in developed areas of the
world [43].
Bladder cancer mortality increased appreciably in men in
the early 1970s, but levelled off thereafter to relatively low
rates on a worldwide scale. These trends were consistent with
those observed for lung and other tobacco-related cancers, and
consequently with a decrease in tobacco consumption in
recent decades [27], as tobacco is the single major recognised
risk factor for bladder cancer on a population level [44].
Mortality from leukaemias showed a rising trend for both
sexes, in contrast to a tendency to decline in most developed
areas of the world over recent decades following the adoption
of integrated therapy regimens, mainly in children and young
adults [45]. As for testicular cancer, this would suggest some
delay in the adoption of modern effective therapy schemes,
although Mexican mortality rates for leukaemias remain rela-
tively low on a worldwide scale [1]. It is, however, possible
that these trends were also influenced by the improved accu-
racy of diagnosis and certification [20].
In conclusion, although the increasing trends in mortality
for lung and other tobacco-related neoplasms have tended to
level off in Mexico over the last decade, steady rises have
been observed for other major cancers, including breast and
prostate. Uterine (mainly cervical) cancer remains a major
health problem in Mexican women, with declines appreciably
lower than those reported in the United States and Europe
[25], and still very high mortality rates on a worldwide scale.
Favourable trends in cancer mortality in Mexico in the near
future would therefore require an integrated strategy of pre-
vention focused on control of tobacco and other lifestyle risk
factors, as well as on early diagnosis, mainly for cervical can-
cer, and the adoption of therapeutic advancements for selected
neoplasms amenable to treatment.
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